Lyra Therapeutics, Inc. (LYRA)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Harlan W. Waksal M.D. | Executive Chairman | 210.06k | -- | 1953 |
| Dr. Maria Palasis Ph.D. | CEO, President & Director | 942.7k | -- | 1965 |
| Dr. John E. Bishop Ph.D. | Chief Technology Officer | 662.9k | -- | 1962 |
| Dr. Carmichael S. Roberts Jr., Ph.D. | Co-Founder | -- | -- | 1969 |
| Mr. Jason Cavalier | CFO, Treasurer & Secretary | 464.11k | -- | 1973 |
| Mr. Ray Knox | Vice President of Operations | -- | -- | -- |
| Ms. Ellen Cavaleri | Senior Vice President of Investor Relations & Communications | -- | -- | -- |
| Mr. Ronan P. O'Brien J.D. | Chief Legal Officer | -- | -- | 1973 |
| Ms. Corinne Noyes | Senior Vice President of Commercial Strategy & Market Development | 426.73k | -- | 1968 |
| Ms. Vineeta Belanger Ph.D. | Senior Vice President of Clinical Affairs | -- | -- | -- |
Lyra Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 109
Description
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Upcoming Events
August 6, 2024 at 10:59 AM UTC - August 12, 2024 at 12:00 PM UTC
Lyra Therapeutics, Inc. Earnings Date
Recent Events
March 28, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission